Pages
-
-
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
-
-
SELNET clinical practice guidelines for soft tissue sarcoma and GIST (vol 102, 102312, 2021)
-
-
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC- Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas
-
-
New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients
-
-
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments
-
-
First-line chemotherapy in advanced intrabdominal well-differentiated/dedifferentiated liposarcoma
-
-
Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas
-
-
Gastrointestinal stromal tumours
-
-
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
-
-
Bone sarcomas
-
-
Soft tissue and visceral sarcomas
-
-
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE
-
-
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcoma
-
-
Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts
-
-
Ultra-rare sarcomas
-
-
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II tri
-
-
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma
-
-
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial
-
-
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
-
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
-
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg 51, 2018)
-
-
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
-
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma G
-
-
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'
Pages